Zinbryta (daclizumab Beta) - Voluntary Withdrawal In Canada Due To Risk Of Encephalitis

Zinbryta (daclizumab beta), a medication used to treat multiple sclerosis, is being withdrawn from the Canadian market because it poses a risk of encephalitis, a serious brain inflammation. The drug has been distributed across Canada. This withdrawal applies to all Canadian patients currently taking or prescribed this medication.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2018-03-16

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/c613e12c-682b-4356-abb1-73da9df6727d